15 Drug Makers See 3.6% Negative Growth in Japan in FY2020 as Re-Pricing, Generic Entries Weigh: Jiho Tally

Fifteen Japanese drug makers foresee an average negative growth of 3.6% in Japan ethical drug sales in FY2020, as some are braced for sharp declines stemming from price cuts and generic inroads as well as the wind-up of major copromotion...read more